The Multiple Myeloma Channel on VJHemOnc is an independent medical education platform, supported with funding from BMS (Gold) and Legend Biotech (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
ASH 2022 | Multiomics profiling of MRD to understand the biology of drug resistance in multiple myeloma
Bruno Paiva, PhD, University of Navarra, Pamplona, Spain, highlights findings made from a study that conducted multiomics profiling of patients with multiple myeloma at diagnosis and relapse after different treatment modalities to further understand measurable residual disease (MRD) resistance. It was shown that the MRD clone is a genetically unique entity within the evolution of the disease, a finding that could inform how MRD resistance is tackled in the future. This interview took place at the 64th ASH Annual Meeting and Exposition congress in New Orleans, LA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Disclosures
Takeda: Honoraria, Research Funding; Adaptive: Honoraria; GSK: Honoraria, Research Funding; EngMab: Research Funding; Sanofi: Consultancy, Honoraria, Research Funding; Janssen: Consultancy, Honoraria; Bristol-Myers Squibb: Consultancy, Honoraria, Research Funding; Roche Glycart AG: Honoraria, Research Funding; Amgen: Honoraria; Gilead: Honoraria; Oncopeptides: Honoraria.
